drugset / Trial / NCT07206849
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Phase 2
Not yet recruiting
79 enrolled
Nationwide Children's Hospital
Day One Biopharmaceuticals, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.
Timeline
- Start
- 2026-05
- Primary completion
- 2030-05
- Completion
- 2037-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tovorafenib | Small molecule | 380 mg/m2 | Oral |